NewsBenzingaAscendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50 Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50 Benzinga 2026.10.01 09:21 (GMT+0) Open on Benzinga Other news Elon Musk’s Tesla Just Secured a $30B Lifeline — BNP Warns the Real Funding Need May Be Much Bigger Mayville Engineering Acquires Finishing Facility In Georgia To Expand Operations; Expects To Invest ~$25M-$30M In Phases Through 2028 Lyft Settles With State Of California For $272.5M, Subject To Court Approval; Recorded $210M Accrual In Q4 2025; Confirms There Have Been No Changes To Q3 2026 Gross Bookings, Adjusted EBITDA, And Adjusted EBITDA Margin HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25 Chuck Schumer Slams Hyde Amendment on 50th Anniversary, Says Abortion Restrictions Force Americans to Choose Between Care, Rent, Food: ‘Health Care Must Not Be a Privilege’ What's Going On With AMD Stock Thursday?
Mayville Engineering Acquires Finishing Facility In Georgia To Expand Operations; Expects To Invest ~$25M-$30M In Phases Through 2028
Lyft Settles With State Of California For $272.5M, Subject To Court Approval; Recorded $210M Accrual In Q4 2025; Confirms There Have Been No Changes To Q3 2026 Gross Bookings, Adjusted EBITDA, And Adjusted EBITDA Margin
HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25
Chuck Schumer Slams Hyde Amendment on 50th Anniversary, Says Abortion Restrictions Force Americans to Choose Between Care, Rent, Food: ‘Health Care Must Not Be a Privilege’
